X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Lilly expands its oncology capabilities into next-generation radioligand therapies by including PNT2002 (177Lu-PNT2002), a PSMA targeted radioligand therapy in development for patients with metastatic castration-resistant prostate cancer.
Lead Product(s): 177Lu-PNT2002
Therapeutic Area: Oncology Product Name: PNT2002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,400.0 million Upfront Cash: $1,400.0 million
Deal Type: Acquisition December 27, 2023
Details:
PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy under phase 3 clinical development for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.
Lead Product(s): [Lu-177]-PNT2002
Therapeutic Area: Oncology Product Name: [Lu-177]-PSMA-I&T
Highest Development Status: Phase IIIProduct Type: Undisclosed
Recipient: Lantheus Holding
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
Through the acquisition, Lilly expands its oncology capabilities into next-generation radioligand therapies by including PNT2002 (177Lu-PNT2002), a PSMA targeted radioligand therapy in development for patients with metastatic castration-resistant prostate cancer.
Lead Product(s): 177Lu-PNT2002
Therapeutic Area: Oncology Product Name: PNT2002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,400.0 million Upfront Cash: $1,400.0 million
Deal Type: Acquisition October 03, 2023
Details:
The collaboration aims to develop and commercialize DARPin in the radioligand therapy field. The parties will collaborate in discovery, candidate selection and preclinical development of Athebody® DARPins for use as Radio-DARPin drug entities.
Lead Product(s): DARPin-targeted Radioligand
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: Athebio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 18, 2023
Details:
The expanded agreement broadens the supply of ITM’s n.c.a. 177Lu to POINT to enable its usage in the clinical and potential future commercial development of the 177Lu-based molecules in POINT’s development pipeline, including 177Lu-PNT2002 for prostate cancer.
Lead Product(s): 177Lu-PNT2002
Therapeutic Area: Oncology Product Name: PNT2002
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Isotope Technologies Munich
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 31, 2023
Details:
The collaboration aims on the development of a global 212Pb radioisotope and radioligand supply chain to specifically support the development and commercialization of 212Pb-labeled radioligands including, 212Pb-ADVC001, a best-in-class treatment for metastatic prostate cancer.
Lead Product(s): 212Pb-ADVC001
Therapeutic Area: Oncology Product Name: 212Pb-ADVC001
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: AdvanCell
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 26, 2023
Details:
PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.
Lead Product(s): 177Lu-PNT2002
Therapeutic Area: Oncology Product Name: PNT2002
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Lantheus Holding
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2023
Details:
Under the agreement, Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POINT for use in the development of POINT’s pipeline of next generation Ac-225-based radioligands, including PSMA-targeted PNT2001 program.
Lead Product(s): PNT2001
Therapeutic Area: Oncology Product Name: PNT2001
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Eckert & Ziegler Strahlen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 04, 2023
Details:
PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.
Lead Product(s): 177Lu-PNT2002
Therapeutic Area: Oncology Product Name: PNT2002
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2023
Details:
PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.
Lead Product(s): 177Lu-PNT2002
Therapeutic Area: Oncology Product Name: PNT2002
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Lantheus Holdings
Deal Size: $2,115.0 million Upfront Cash: $260.0 million
Deal Type: Agreement December 20, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
